Celgene

Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
Flag link:
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
Flag link:
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Motley Fool
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
Flag link:
Celgene invested $30M in NantCell weeks before BMS bid
Celgene invested $30M in NantCell weeks before BMS bid
BioCentury
Celgene
NantCell
Bristol-Myers Squibb
M&A
Flag link:
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Flag link:
After Bristol-Myers Squibb Buys Celgene What's Next? JP Morgan's Conference Will Answer That
After Bristol-Myers Squibb Buys Celgene What's Next? JP Morgan's Conference Will Answer That
Forbes
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
Flag link:
BMS CEO Giovanni Caforio Lays out Reasoning for $74 Billion Acquisition of Celgene
BMS CEO Giovanni Caforio Lays out Reasoning for $74 Billion Acquisition of Celgene
BioSpace
Bristol-Myers Squibb
M&A
Giovanni Caforio
Celgene
Flag link:
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Fierce Pharma
M&A
Bristol-Myers Squibb
Celgene
Gilead Sciences
AbbVie
Amgen
Flag link:
Celgene executives whipped up new, lucrative severance plans ahead of Bristol-Myers megadeal
Celgene executives whipped up new, lucrative severance plans ahead of Bristol-Myers megadeal
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
severance
executive pay
Flag link:
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
Revlimid
patents
Flag link:
Should Celgene Investors Take Bristol's Money and Run?
Should Celgene Investors Take Bristol's Money and Run?
Motley Fool
Celgene
Bristol-Myers Squibb
M&A
Flag link:
Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene
Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene
Yahoo/Motley Fool
M&A
Celgene
Bristol-Myers Squibb
Flag link:
Bristol-Myers Squibb And Celgene's Big Winner? Los Angeles Billionaire Patrick Soon-Shiong
Bristol-Myers Squibb And Celgene's Big Winner? Los Angeles Billionaire Patrick Soon-Shiong
Forbes
Patrick Soon-Shiong
Bristol-Myers Squibb
Celgene
M&A
Flag link:
BMS deal weighs on Celgene partners
BMS deal weighs on Celgene partners
BioCentury
M&A
Celgene
Bristol-Myers Squibb
Acceleron
BeiGene
Flag link:
Bristol-Myers to buy Celgene in industry-shaking $74B deal
Bristol-Myers to buy Celgene in industry-shaking $74B deal
Biopharma Dive
M&A
Bristol-Myers Squibb
Celgene
immuno-oncology
Flag link:
Celgene invests in Chinese biotech Antengene again
Celgene invests in Chinese biotech Antengene again
Fierce Biotech
Celgene
Antengene
China
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
3 Biotechs With Potential Blockbusters Near the Finish Line
3 Biotechs With Potential Blockbusters Near the Finish Line
Motley Fool
Vertex Pharmaceuticals
VX-659 + tezacaftor + ivacaftor
Celgene
JCAR017
Novo Nordisk
semaglutide
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
Flag link:

Pages